Treatment for Parkinson Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of California San Diego, San Diego, CA
Parkinson Disease+6 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing. About one-third of people with PD have OH, which can cause sudden, temporary symptoms while upright, including lightheadedness, dizziness, and fainting. People with PD and OH can also experience problems thinking that happen only while upright and not while sitting - this can occur without other symptoms, such as feeling dizzy or faint. However, the level of low BP that can affect thinking remains unknown, and no guidelines exist for treating OH when it happens without symptoms. This is significant because OH could be a treatable risk factor for thinking problems in PD, but OH is often not treated if people do not report obvious symptoms. This project's goal is to determine how BP affects brain function in PD. The proposed experiments will measure BP and brain blood flow continuously in real-time using innovative wearable technology. People with PD with OH and without OH will undergo repeated cognitive tests while sitting and while upright. I will study the associations between BP, thinking abilities, and brain blood flow, and will compare groups with and without OH. These findings could be important because if a certain level of BP correlates with thinking abilities, then treating OH in PD may prevent thinking problems, which would improve health-related quality of life and reduce disability and healthcare costs.

Eligible Conditions

  • Parkinson Disease
  • Orthostatic Hypotension
  • Dysautonomia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: up to 30 months

up to 30 months
Delis-Kaplan Executive Function System Verbal Fluency Test score (number of words per minute)
Delis-Kaplan Executive Function System Verbal Fluency Test score (number of words per minute). Minimum: 0; Maximum: N/A; higher is better
Oxygenated and deoxygenated hemoglobin change from baseline

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

60 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 30 months
Closest Location: University of California San Diego · San Diego, CA
Photo of University of California San Diego 1Photo of University of California San Diego 2Photo of University of California San Diego 3
2003First Recorded Clinical Trial
7 TrialsResearching Parkinson Disease
263 CompletedClinical Trials

Who is running the clinical trial?

Drexel UniversityOTHER
132 Previous Clinical Trials
42,396 Total Patients Enrolled
Beth Israel Deaconess Medical CenterOTHER
767 Previous Clinical Trials
849,057 Total Patients Enrolled
12 Trials studying Parkinson Disease
664 Patients Enrolled for Parkinson Disease
University of California, San DiegoLead Sponsor
1,007 Previous Clinical Trials
1,793,104 Total Patients Enrolled
5 Trials studying Parkinson Disease
259 Patients Enrolled for Parkinson Disease

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a stage I or II H&Y (early to moderate-stage PD; able to walk without assistance).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References